Xenetic Biosciences’ DNase I Boosts CAR-T Cell Therapy, Enhancing Persistence and Tumor Control in Preclinical Models

**FOR IMMEDIATE RELEASE**

**Xenetic Biosciences Presents Data on DNase I Enhancement of CAR-T Cell Therapy at ASCO 2026**

CHICAGO, IL – June 1, 2026 – Xenetic Biosciences presented data at the American Society of Clinical Oncology (ASCO) 2026 meeting, highlighting the potential of DNase I to significantly improve the effectiveness of CAR-T cell therapy. The data indicated that DNase I enhances CAR-T cell persistence, tumor control, and overall survival in preclinical models.

The study results demonstrated that the addition of DNase I to CAR-T cell therapy led to a notable increase in the duration that CAR-T cells remained active within the body. Researchers also observed improved tumor control in preclinical models treated with the combined therapy. Furthermore, the data suggested a significant improvement in survival rates among the subjects receiving DNase I in conjunction with CAR-T cell treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI